

What is claimed is:

1. A pharmaceutical composition comprising (a) an oral contraceptive for preventing pregnancy in a subject, and (b) folic acid in an amount sufficient to treat or prevent a disorder which (i) afflicts subjects for whom the oral contraceptive is indicated at a higher-than-normal incidence, and (ii) is treatable or preventable by folic acid administration.
2. The pharmaceutical composition of claim 1, wherein the disorder is selected from the group consisting of a teratogenic disorder, cervical dysplasia, a cervical carcinoma, and a cardiovascular disorder.
3. A pharmaceutical composition comprising (a) a hormonal replacement composition for treating or preventing a menopausal condition in a subject, and (b) folic acid in an amount sufficient to treat or prevent a disorder which (i) afflicts subjects for whom the hormonal replacement composition is indicated at a higher-than-normal incidence, and (ii) is treatable or preventable by folic acid administration.
4. The pharmaceutical composition of claim 3, wherein the menopausal condition is a peri-menopausal condition.
5. The pharmaceutical composition of claim 3, wherein the menopausal condition is a post-menopausal condition.

6. The pharmaceutical composition of claim 3, wherein the disorder is selected from the group consisting of cervical dysplasia, a cervical carcinoma, and a cardiovascular disorder.

7. A pharmaceutical composition comprising (a) a hormonal replacement composition for treating or preventing a hypogonadal condition in a subject, and (b) folic acid in an amount sufficient to treat or prevent a disorder which (i) afflicts subjects for whom the hormonal replacement composition is indicated at a higher-than-normal incidence, and (ii) is treatable or preventable by folic acid administration.

8. The pharmaceutical composition of claim 7, wherein the subject is female, and the disorder is selected from the group consisting of a teratogenic disorder, cervical dysplasia, a cervical carcinoma, and a cardiovascular disorder.

9. The pharmaceutical composition of claim 7, wherein the subject is male, and the disorder is a cardiovascular disorder.

10. A method of administering folic acid to a subject for whom an oral contraceptive is indicated for preventing pregnancy, which comprises administering to the subject the pharmaceutical composition of claim 1, wherein the subject is from a population whose members are afflicted with, or predisposed to become afflicted with, a disorder at a higher-than-normal incidence, the disorder being treatable or preventable by folic acid administration.

006007 92622580

- 11. The method of claim 10, wherein the disorder is selected from the group consisting of a teratogenic disorder, cervical dysplasia, a cervical carcinoma, and a cardiovascular disorder.
- 12. A method of administering folic acid to a subject for whom a hormonal replacement composition is indicated for treating or preventing a menopausal condition, which comprises administering to the subject the pharmaceutical composition of claim 3, wherein the subject is from a population whose members are afflicted with, or predisposed to become afflicted with, a disorder at a higher-than-normal incidence, the disorder being treatable or preventable by folic acid administration.
- 13. The method of claim 12, wherein the menopausal condition is a peri-menopausal condition.
- 14. The method of claim 12, wherein the menopausal condition is a post-menopausal condition.
- 15. The method of claim 12, wherein the disorder is selected from the group consisting of cervical dysplasia, a cervical carcinoma, and a cardiovascular disorder.
- 16. A method of administering folic acid to a subject for whom a hormonal replacement composition is indicated for treating or preventing a hypogonadal condition, which comprises administering to the subject the pharmaceutical composition of claim 7, wherein the subject is from a population whose

members are afflicted with, or predisposed to become afflicted with, a disorder at a higher-than-normal incidence, the disorder being treatable or preventable by folic acid administration.

5

17. The method of claim 16, wherein the subject is female, and the disorder is selected from the group consisting of a teratogenic disorder, cervical dysplasia, a cervical carcinoma, and a cardiovascular disorder.

10

18. The method of claim 16, wherein the subject is male, and the disorder is a cardiovascular disorder.

15

19. A drug delivery system comprising a pharmaceutical package containing a plurality of dosage units, adapted for successive daily administration, wherein each dosage unit comprises a pharmaceutical composition selected from the group consisting of an oral contraceptive and a hormonal replacement composition.

20

20. The drug delivery system of claim 19, wherein each dosage unit comprises an oral contraceptive.

25

add A3